New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
07:59 EDTGEVASynageva should be bought at current levels, says RW Baird
Baird said their investment thesis for Synageva remains unchanged following its successful display at the WORLD symposium last month. The firm recommends purchase at current levels as the company heads into an important value-creating period which includes potential pivotal data for a lead compound and the beginning of clinical trials for SBC-103. Shares are Outperform rated with a $107 price target.
News For GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
16:32 EDTGEVASynageva reports sebelipase alfa data at NASPGHAN meeting
Subscribe for More Information
October 21, 2014
16:19 EDTGEVASynageva announces submission of BLA to the FDA for sebelipase
Synageva BioPharma announced the start of a rolling submission of a Biologics License Application, or BLA, to the FDA for sebelipase alfa as a treatment for patients with lysosomal acid lipase deficiency, a rare genetic disease with significant morbidity and early mortality. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The company anticipates completing the rolling submission of the BLA to the FDA and submitting the Marketing Authorization Application to the European Medicines Agency) by the end of January 2015.
09:48 EDTGEVAShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
October 16, 2014
10:01 EDTGEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:53 EDTGEVASynageva initiated with a Buy at SunTrust
Target $117.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use